Sarah M. Berger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sarah M. Berger has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Laura M. Kühner
Center for Virology, Medical University of Vienna, Vienna, Austria
4 shared publications Elisabeth Puchhammer-Stöckl
Center for Virology, Medical University of Vienna
3 shared publications- Hannes Vietzen
Center for Virology, Medical University of Vienna
3 shared publications Barbara Kornek
Department of Neurology, Medical University of Vienna
2 shared publicationsFranziska Kauth
Department of Pediatric Neurology, Children´s Hospital Datteln, Witten/Herdecke University
2 shared publicationsHenrieke Saucke
Department of Pediatric Neurology, Children´s Hospital Datteln, Witten/Herdecke University
2 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (40)
Impaired control of autoimmunity increases pediatric multiple sclerosis risk in EBNA-1-seropositives and -seronegatives
Multiple sclerosis (MS) is an autoinflammatory disease of the central nervous system (CNS). Epstein–Barr virus (EBV) encodes for EBNA-1 381-452 , which induces autoreactive immune responses against distinct CNS derived proteins (GlialCAM 370-389 , CRYAB 2-21 , MBP 205-224 , ANO2 135-154 ). Although EBV infection is considered essential for MS development, CNS-specific autoimmune responses may also be present in putatively EBV EBNA-1-seronegative patients, warranting further investigation. We studied 548 EBV EBNA-1 seropositive and 30 EBV EBNA-1 seronegative pediatric-onset MS (POMS) patients, along with 578 matched controls. CNS specific antibodies were significantly more prevalent in EBV EBNA-1 seropositive POMS patients (92.2%) than in EBV EBNA-1 seropositive controls (56.3%, P < 0.0001). However, high CNS specific antibody levels were also found in 56.6% of EBV EBNA-1 seronegative POMS patients and 17.4% of EBV EBNA-1 seronegative controls. These findings suggest that while EBV infection amplifies CNS specific autoimmune responses, high-level CNS autoreactive autoimmune responses can also occur independently of EBV EBNA-1. We further evaluated why only some individuals with high-level CNS autoreactive antibody titers develop MS. Mechanistically, we demonstrate that autoreactive immune responses are effectively controlled by NKG2C + and NKG2D + natural killer (NK) cells. These findings indicate that CNS-specific autoimmunity and impaired NK cell regulation, rather than EBV alone, are central to MS risk.
- 1 October 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (40)
Open AccessImpaired control of autoimmunity increases pediatric multiple sclerosis risk in EBNA-1-seropositives and -seronegatives
Multiple sclerosis (MS) is an autoinflammatory disease of the central nervous system (CNS). Epstein–Barr virus (EBV) encodes for EBNA-1 381-452 , which induces autoreactive immune responses against distinct CNS derived proteins (GlialCAM 370-389 , CRYAB 2-21 , MBP 205-224 , ANO2 135-154 ). Although EBV infection is considered essential for MS development, CNS-specific autoimmune responses may also be present in putatively EBV EBNA-1-seronegative patients, warranting further investigation. We studied 548 EBV EBNA-1 seropositive and 30 EBV EBNA-1 seronegative pediatric-onset MS (POMS) patients, along with 578 matched controls. CNS specific antibodies were significantly more prevalent in EBV EBNA-1 seropositive POMS patients (92.2%) than in EBV EBNA-1 seropositive controls (56.3%, P < 0.0001). However, high CNS specific antibody levels were also found in 56.6% of EBV EBNA-1 seronegative POMS patients and 17.4% of EBV EBNA-1 seronegative controls. These findings suggest that while EBV infection amplifies CNS specific autoimmune responses, high-level CNS autoreactive autoimmune responses can also occur independently of EBV EBNA-1. We further evaluated why only some individuals with high-level CNS autoreactive antibody titers develop MS. Mechanistically, we demonstrate that autoreactive immune responses are effectively controlled by NKG2C + and NKG2D + natural killer (NK) cells. These findings indicate that CNS-specific autoimmunity and impaired NK cell regulation, rather than EBV alone, are central to MS risk.
- Open Access
- 25 May 2026
- Published by S. Karger AG in Journal of Innate Immunity
- Vol. 18 (1) , 1-11
Association of CD32-131H>R Polymorphism with End-Stage COPD and Interstitial Lung Diseases
Introduction: Progression to end-stage lung diseases is influenced by both environmental and genetic factors, yet predictive markers remain limited. The CD32-131H>R polymorphism in the FCGR2A gene alters the affinity of the FcγRIIa receptor for IgG and may impair immune clearance, potentially influencing immune responses involved in chronic lung disease. In our study, we investigated the association between the CD32-131H>R polymorphism and end-stage pulmonary diseases requiring LTX. Methods: The CD32-131H>R polymorphism was determined in 985 lung transplant recipients and 2,116 matched controls via TaqMan genotyping assays. Results: The low-affinity CD32-131R allele was significantly more prevalent among lung transplant recipients with chronic obstructive pulmonary disease (COPD) and interstitial lung diseases (ILD) compared to controls (p<0.0001 and p=0.01, respectively). Conclusion: Our study demonstrates that the CD32-131R allele is enriched among patients with end-stage COPD and ILD requiring LTX, highlighting a possible association between Fcγ receptor-mediated immune responses and end-stage pulmonary disease.
- 25 May 2026
- Published by S. Karger AG in Journal of Innate Immunity
- Vol. 18 (1) , 1-11
Open AccessAssociation of CD32-131H>R Polymorphism with End-Stage COPD and Interstitial Lung Diseases
Introduction: Progression to end-stage lung diseases is influenced by both environmental and genetic factors, yet predictive markers remain limited. The CD32-131H>R polymorphism in the FCGR2A gene alters the affinity of the FcγRIIa receptor for IgG and may impair immune clearance, potentially influencing immune responses involved in chronic lung disease. In our study, we investigated the association between the CD32-131H>R polymorphism and end-stage pulmonary diseases requiring LTX. Methods: The CD32-131H>R polymorphism was determined in 985 lung transplant recipients and 2,116 matched controls via TaqMan genotyping assays. Results: The low-affinity CD32-131R allele was significantly more prevalent among lung transplant recipients with chronic obstructive pulmonary disease (COPD) and interstitial lung diseases (ILD) compared to controls (p<0.0001 and p=0.01, respectively). Conclusion: Our study demonstrates that the CD32-131R allele is enriched among patients with end-stage COPD and ILD requiring LTX, highlighting a possible association between Fcγ receptor-mediated immune responses and end-stage pulmonary disease.
- Open Access
- 14 July 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-11
Early identification of individuals at risk for multiple sclerosis by quantification of EBNA-1381-452-specific antibody titers
Multiple sclerosis (MS) is an immune-mediated demyelinating disease. Epstein-Barr virus (EBV) encodes for the EBNA-1381-452 region that induces autoreactive antibody responses, which are likely critically involved in MS pathogenesis. Here we investigate whether these EBNA-1381-452-specific antibodies can serve as a biomarker to identify at-risk individuals for MS. We quantify EBNA-1381-452-specific antibody titers from 324 relapsing-remitting MS patients and 324 matched controls in longitudinal follow-up plasma samples, starting from the individual’s EBV-seroconversion. In MS patients, significantly elevated EBNA-1381-452-specific IgG titers are identified that are increased already as early as nine months after EBV-seroconversion (OR:5.7; 95% CI: 4.1-8.1; P < 0.0001) and a median 5.4 years prior to MS diagnosis. Especially, the presence of continuously high EBNA-1381-452-specific antibody titers is associated with a more rapid MS diagnosis after EBV-seroconversion (P < 0.0001). Thus, the quantification of EBNA-1381-452-specific IgG antibody levels may provide a prognostic biomarker to determine the individual’s risk for the diagnosis of MS.
- 14 July 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-11
Open AccessEarly identification of individuals at risk for multiple sclerosis by quantification of EBNA-1381-452-specific antibody titers
Multiple sclerosis (MS) is an immune-mediated demyelinating disease. Epstein-Barr virus (EBV) encodes for the EBNA-1381-452 region that induces autoreactive antibody responses, which are likely critically involved in MS pathogenesis. Here we investigate whether these EBNA-1381-452-specific antibodies can serve as a biomarker to identify at-risk individuals for MS. We quantify EBNA-1381-452-specific antibody titers from 324 relapsing-remitting MS patients and 324 matched controls in longitudinal follow-up plasma samples, starting from the individual’s EBV-seroconversion. In MS patients, significantly elevated EBNA-1381-452-specific IgG titers are identified that are increased already as early as nine months after EBV-seroconversion (OR:5.7; 95% CI: 4.1-8.1; P < 0.0001) and a median 5.4 years prior to MS diagnosis. Especially, the presence of continuously high EBNA-1381-452-specific antibody titers is associated with a more rapid MS diagnosis after EBV-seroconversion (P < 0.0001). Thus, the quantification of EBNA-1381-452-specific IgG antibody levels may provide a prognostic biomarker to determine the individual’s risk for the diagnosis of MS.
- Open Access
- 13 December 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 24 (5) , 743-754
Natural killer cell functional genetics and donor-specific antibody-triggered microvascular inflammation
- 13 December 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 24 (5) , 743-754
Open AccessNatural killer cell functional genetics and donor-specific antibody-triggered microvascular inflammation